Global IBS Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028
The IBS Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global IBS Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the IBS Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While IBS-D segment is altered to a % CAGR between 2022 and 2028.
Global key companies of IBS Treatment include Allergan (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals (U.S.), Astellas Pharma (Japan), and Bausch Health, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
IBS Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
IBS-D
IBS-C
IBS-M
Market segment by Application, can be divided into
Hospitals
Clinics
Research Laboratories
Market segment by players, this report covers
Allergan (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Astellas Pharma (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals (U.S.)
Ardelyx (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA (Italy)
RedHill Biopharma (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis (Switzerland)
Takeda Pharmaceutical Company (Japan)
Synthetic Biologics (U.S.)
Protagonist Therapeutics (U.S.)
Pfizer (U.S.)
Lexicon Pharmaceuticals (U.S.)
Innovate Biopharmaceuticals (U.S.)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe IBS Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of IBS Treatment, with revenue, gross margin and global market share of IBS Treatment from 2019 to 2022.
Chapter 3, the IBS Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and IBS Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe IBS Treatment research findings and conclusion, appendix and data source.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of IBS Treatment
1.2 Classification of IBS Treatment by Type
1.2.1 Overview: Global IBS Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global IBS Treatment Revenue Market Share by Type in 2021
1.2.3 IBS-D
1.2.4 IBS-C
1.2.5 IBS-M
1.3 Global IBS Treatment Market by Application
1.3.1 Overview: Global IBS Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Laboratories
1.4 Global IBS Treatment Market Size & Forecast
1.5 Global IBS Treatment Market Size and Forecast by Region
1.5.1 Global IBS Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global IBS Treatment Market Size by Region, (2017-2022)
1.5.3 North America IBS Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe IBS Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific IBS Treatment Market Size and Prospect (2017-2028)
1.5.6 South America IBS Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa IBS Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 IBS Treatment Market Drivers
1.6.2 IBS Treatment Market Restraints
1.6.3 IBS Treatment Trends Analysis
2 Company Profiles
2.1 Allergan (Ireland)
2.1.1 Allergan (Ireland) Details
2.1.2 Allergan (Ireland) Major Business
2.1.3 Allergan (Ireland) IBS Treatment Product and Solutions
2.1.4 Allergan (Ireland) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Allergan (Ireland) Recent Developments and Future Plans
2.2 Sucampo Pharmaceuticals (U.S.)
2.2.1 Sucampo Pharmaceuticals (U.S.) Details
2.2.2 Sucampo Pharmaceuticals (U.S.) Major Business
2.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Product and Solutions
2.2.4 Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Sucampo Pharmaceuticals (U.S.) Recent Developments and Future Plans
2.3 Ironwood Pharmaceuticals (U.S.)
2.3.1 Ironwood Pharmaceuticals (U.S.) Details
2.3.2 Ironwood Pharmaceuticals (U.S.) Major Business
2.3.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Product and Solutions
2.3.4 Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Ironwood Pharmaceuticals (U.S.) Recent Developments and Future Plans
2.4 Astellas Pharma (Japan)
2.4.1 Astellas Pharma (Japan) Details
2.4.2 Astellas Pharma (Japan) Major Business
2.4.3 Astellas Pharma (Japan) IBS Treatment Product and Solutions
2.4.4 Astellas Pharma (Japan) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Astellas Pharma (Japan) Recent Developments and Future Plans
2.5 Bausch Health
2.5.1 Bausch Health Details
2.5.2 Bausch Health Major Business
2.5.3 Bausch Health IBS Treatment Product and Solutions
2.5.4 Bausch Health IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Bausch Health Recent Developments and Future Plans
2.6 Abbott Laboratories (U.S.)
2.6.1 Abbott Laboratories (U.S.) Details
2.6.2 Abbott Laboratories (U.S.) Major Business
2.6.3 Abbott Laboratories (U.S.) IBS Treatment Product and Solutions
2.6.4 Abbott Laboratories (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Abbott Laboratories (U.S.) Recent Developments and Future Plans
2.7 Synergy Pharmaceuticals (U.S.)
2.7.1 Synergy Pharmaceuticals (U.S.) Details
2.7.2 Synergy Pharmaceuticals (U.S.) Major Business
2.7.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Product and Solutions
2.7.4 Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Synergy Pharmaceuticals (U.S.) Recent Developments and Future Plans
2.8 Ardelyx (U.S.)
2.8.1 Ardelyx (U.S.) Details
2.8.2 Ardelyx (U.S.) Major Business
2.8.3 Ardelyx (U.S.) IBS Treatment Product and Solutions
2.8.4 Ardelyx (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Ardelyx (U.S.) Recent Developments and Future Plans
2.9 Nestle (Switzerland)
2.9.1 Nestle (Switzerland) Details
2.9.2 Nestle (Switzerland) Major Business
2.9.3 Nestle (Switzerland) IBS Treatment Product and Solutions
2.9.4 Nestle (Switzerland) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Nestle (Switzerland) Recent Developments and Future Plans
2.10 Sebela Pharmaceuticals (Ireland)
2.10.1 Sebela Pharmaceuticals (Ireland) Details
2.10.2 Sebela Pharmaceuticals (Ireland) Major Business
2.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Product and Solutions
2.10.4 Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Sebela Pharmaceuticals (Ireland) Recent Developments and Future Plans
2.11 Probi (Sweden)
2.11.1 Probi (Sweden) Details
2.11.2 Probi (Sweden) Major Business
2.11.3 Probi (Sweden) IBS Treatment Product and Solutions
2.11.4 Probi (Sweden) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Probi (Sweden) Recent Developments and Future Plans
2.12 Alfasigma USA (Italy)
2.12.1 Alfasigma USA (Italy) Details
2.12.2 Alfasigma USA (Italy) Major Business
2.12.3 Alfasigma USA (Italy) IBS Treatment Product and Solutions
2.12.4 Alfasigma USA (Italy) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Alfasigma USA (Italy) Recent Developments and Future Plans
2.13 RedHill Biopharma (Israel)
2.13.1 RedHill Biopharma (Israel) Details
2.13.2 RedHill Biopharma (Israel) Major Business
2.13.3 RedHill Biopharma (Israel) IBS Treatment Product and Solutions
2.13.4 RedHill Biopharma (Israel) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 RedHill Biopharma (Israel) Recent Developments and Future Plans
2.14 AstraZeneca (U.K)
2.14.1 AstraZeneca (U.K) Details
2.14.2 AstraZeneca (U.K) Major Business
2.14.3 AstraZeneca (U.K) IBS Treatment Product and Solutions
2.14.4 AstraZeneca (U.K) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 AstraZeneca (U.K) Recent Developments and Future Plans
2.15 Ipsen (France)
2.15.1 Ipsen (France) Details
2.15.2 Ipsen (France) Major Business
2.15.3 Ipsen (France) IBS Treatment Product and Solutions
2.15.4 Ipsen (France) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Ipsen (France) Recent Developments and Future Plans
2.16 Novartis (Switzerland)
2.16.1 Novartis (Switzerland) Details
2.16.2 Novartis (Switzerland) Major Business
2.16.3 Novartis (Switzerland) IBS Treatment Product and Solutions
2.16.4 Novartis (Switzerland) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Novartis (Switzerland) Recent Developments and Future Plans
2.17 Takeda Pharmaceutical Company (Japan)
2.17.1 Takeda Pharmaceutical Company (Japan) Details
2.17.2 Takeda Pharmaceutical Company (Japan) Major Business
2.17.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Product and Solutions
2.17.4 Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Takeda Pharmaceutical Company (Japan) Recent Developments and Future Plans
2.18 Synthetic Biologics (U.S.)
2.18.1 Synthetic Biologics (U.S.) Details
2.18.2 Synthetic Biologics (U.S.) Major Business
2.18.3 Synthetic Biologics (U.S.) IBS Treatment Product and Solutions
2.18.4 Synthetic Biologics (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Synthetic Biologics (U.S.) Recent Developments and Future Plans
2.19 Protagonist Therapeutics (U.S.)
2.19.1 Protagonist Therapeutics (U.S.) Details
2.19.2 Protagonist Therapeutics (U.S.) Major Business
2.19.3 Protagonist Therapeutics (U.S.) IBS Treatment Product and Solutions
2.19.4 Protagonist Therapeutics (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Protagonist Therapeutics (U.S.) Recent Developments and Future Plans
2.20 Pfizer (U.S.)
2.20.1 Pfizer (U.S.) Details
2.20.2 Pfizer (U.S.) Major Business
2.20.3 Pfizer (U.S.) IBS Treatment Product and Solutions
2.20.4 Pfizer (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Pfizer (U.S.) Recent Developments and Future Plans
2.21 Lexicon Pharmaceuticals (U.S.)
2.21.1 Lexicon Pharmaceuticals (U.S.) Details
2.21.2 Lexicon Pharmaceuticals (U.S.) Major Business
2.21.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Product and Solutions
2.21.4 Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Lexicon Pharmaceuticals (U.S.) Recent Developments and Future Plans
2.22 Innovate Biopharmaceuticals (U.S.)
2.22.1 Innovate Biopharmaceuticals (U.S.) Details
2.22.2 Innovate Biopharmaceuticals (U.S.) Major Business
2.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Product and Solutions
2.22.4 Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 Innovate Biopharmaceuticals (U.S.) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global IBS Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 IBS Treatment Players Market Share in 2021
3.2.2 Top 10 IBS Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 IBS Treatment Players Head Office, Products and Services Provided
3.4 IBS Treatment Mergers & Acquisitions
3.5 IBS Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global IBS Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global IBS Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global IBS Treatment Revenue Market Share by Application (2017-2022)
5.2 Global IBS Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America IBS Treatment Revenue by Type (2017-2028)
6.2 North America IBS Treatment Revenue by Application (2017-2028)
6.3 North America IBS Treatment Market Size by Country
6.3.1 North America IBS Treatment Revenue by Country (2017-2028)
6.3.2 United States IBS Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada IBS Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico IBS Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe IBS Treatment Revenue by Type (2017-2028)
7.2 Europe IBS Treatment Revenue by Application (2017-2028)
7.3 Europe IBS Treatment Market Size by Country
7.3.1 Europe IBS Treatment Revenue by Country (2017-2028)
7.3.2 Germany IBS Treatment Market Size and Forecast (2017-2028)
7.3.3 France IBS Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom IBS Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia IBS Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy IBS Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific IBS Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific IBS Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific IBS Treatment Market Size by Region
8.3.1 Asia-Pacific IBS Treatment Revenue by Region (2017-2028)
8.3.2 China IBS Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan IBS Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea IBS Treatment Market Size and Forecast (2017-2028)
8.3.5 India IBS Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia IBS Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia IBS Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America IBS Treatment Revenue by Type (2017-2028)
9.2 South America IBS Treatment Revenue by Application (2017-2028)
9.3 South America IBS Treatment Market Size by Country
9.3.1 South America IBS Treatment Revenue by Country (2017-2028)
9.3.2 Brazil IBS Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina IBS Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa IBS Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa IBS Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa IBS Treatment Market Size by Country
10.3.1 Middle East & Africa IBS Treatment Revenue by Country (2017-2028)
10.3.2 Turkey IBS Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia IBS Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE IBS Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global IBS Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global IBS Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market IBS Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global IBS Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global IBS Treatment Revenue Market Share by Region (2023-2028)
Table 6. Allergan (Ireland) Corporate Information, Head Office, and Major Competitors
Table 7. Allergan (Ireland) Major Business
Table 8. Allergan (Ireland) IBS Treatment Product and Solutions
Table 9. Allergan (Ireland) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Sucampo Pharmaceuticals (U.S.) Corporate Information, Head Office, and Major Competitors
Table 11. Sucampo Pharmaceuticals (U.S.) Major Business
Table 12. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product and Solutions
Table 13. Sucampo Pharmaceuticals (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Ironwood Pharmaceuticals (U.S.) Corporate Information, Head Office, and Major Competitors
Table 15. Ironwood Pharmaceuticals (U.S.) Major Business
Table 16. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product and Solutions
Table 17. Ironwood Pharmaceuticals (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Astellas Pharma (Japan) Corporate Information, Head Office, and Major Competitors
Table 19. Astellas Pharma (Japan) Major Business
Table 20. Astellas Pharma (Japan) IBS Treatment Product and Solutions
Table 21. Astellas Pharma (Japan) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Bausch Health Corporate Information, Head Office, and Major Competitors
Table 23. Bausch Health Major Business
Table 24. Bausch Health IBS Treatment Product and Solutions
Table 25. Bausch Health IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Abbott Laboratories (U.S.) Corporate Information, Head Office, and Major Competitors
Table 27. Abbott Laboratories (U.S.) Major Business
Table 28. Abbott Laboratories (U.S.) IBS Treatment Product and Solutions
Table 29. Abbott Laboratories (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Synergy Pharmaceuticals (U.S.) Corporate Information, Head Office, and Major Competitors
Table 31. Synergy Pharmaceuticals (U.S.) Major Business
Table 32. Synergy Pharmaceuticals (U.S.) IBS Treatment Product and Solutions
Table 33. Synergy Pharmaceuticals (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Ardelyx (U.S.) Corporate Information, Head Office, and Major Competitors
Table 35. Ardelyx (U.S.) Major Business
Table 36. Ardelyx (U.S.) IBS Treatment Product and Solutions
Table 37. Ardelyx (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Nestle (Switzerland) Corporate Information, Head Office, and Major Competitors
Table 39. Nestle (Switzerland) Major Business
Table 40. Nestle (Switzerland) IBS Treatment Product and Solutions
Table 41. Nestle (Switzerland) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Sebela Pharmaceuticals (Ireland) Corporate Information, Head Office, and Major Competitors
Table 43. Sebela Pharmaceuticals (Ireland) Major Business
Table 44. Sebela Pharmaceuticals (Ireland) IBS Treatment Product and Solutions
Table 45. Sebela Pharmaceuticals (Ireland) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Probi (Sweden) Corporate Information, Head Office, and Major Competitors
Table 47. Probi (Sweden) Major Business
Table 48. Probi (Sweden) IBS Treatment Product and Solutions
Table 49. Probi (Sweden) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Alfasigma USA (Italy) Corporate Information, Head Office, and Major Competitors
Table 51. Alfasigma USA (Italy) Major Business
Table 52. Alfasigma USA (Italy) IBS Treatment Product and Solutions
Table 53. Alfasigma USA (Italy) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. RedHill Biopharma (Israel) Corporate Information, Head Office, and Major Competitors
Table 55. RedHill Biopharma (Israel) Major Business
Table 56. RedHill Biopharma (Israel) IBS Treatment Product and Solutions
Table 57. RedHill Biopharma (Israel) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. AstraZeneca (U.K) Corporate Information, Head Office, and Major Competitors
Table 59. AstraZeneca (U.K) Major Business
Table 60. AstraZeneca (U.K) IBS Treatment Product and Solutions
Table 61. AstraZeneca (U.K) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Ipsen (France) Corporate Information, Head Office, and Major Competitors
Table 63. Ipsen (France) Major Business
Table 64. Ipsen (France) IBS Treatment Product and Solutions
Table 65. Ipsen (France) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Novartis (Switzerland) Corporate Information, Head Office, and Major Competitors
Table 67. Novartis (Switzerland) Major Business
Table 68. Novartis (Switzerland) IBS Treatment Product and Solutions
Table 69. Novartis (Switzerland) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Takeda Pharmaceutical Company (Japan) Corporate Information, Head Office, and Major Competitors
Table 71. Takeda Pharmaceutical Company (Japan) Major Business
Table 72. Takeda Pharmaceutical Company (Japan) IBS Treatment Product and Solutions
Table 73. Takeda Pharmaceutical Company (Japan) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Synthetic Biologics (U.S.) Corporate Information, Head Office, and Major Competitors
Table 75. Synthetic Biologics (U.S.) Major Business
Table 76. Synthetic Biologics (U.S.) IBS Treatment Product and Solutions
Table 77. Synthetic Biologics (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Protagonist Therapeutics (U.S.) Corporate Information, Head Office, and Major Competitors
Table 79. Protagonist Therapeutics (U.S.) Major Business
Table 80. Protagonist Therapeutics (U.S.) IBS Treatment Product and Solutions
Table 81. Protagonist Therapeutics (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Pfizer (U.S.) Corporate Information, Head Office, and Major Competitors
Table 83. Pfizer (U.S.) Major Business
Table 84. Pfizer (U.S.) IBS Treatment Product and Solutions
Table 85. Pfizer (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Lexicon Pharmaceuticals (U.S.) Corporate Information, Head Office, and Major Competitors
Table 87. Lexicon Pharmaceuticals (U.S.) Major Business
Table 88. Lexicon Pharmaceuticals (U.S.) IBS Treatment Product and Solutions
Table 89. Lexicon Pharmaceuticals (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Innovate Biopharmaceuticals (U.S.) Corporate Information, Head Office, and Major Competitors
Table 91. Innovate Biopharmaceuticals (U.S.) Major Business
Table 92. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product and Solutions
Table 93. Innovate Biopharmaceuticals (U.S.) IBS Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. Global IBS Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 95. Global IBS Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 96. Breakdown of IBS Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 97. IBS Treatment Players Head Office, Products and Services Provided
Table 98. IBS Treatment Mergers & Acquisitions in the Past Five Years
Table 99. IBS Treatment New Entrants and Expansion Plans
Table 100. Global IBS Treatment Revenue (USD Million) by Type (2017-2022)
Table 101. Global IBS Treatment Revenue Share by Type (2017-2022)
Table 102. Global IBS Treatment Revenue Forecast by Type (2023-2028)
Table 103. Global IBS Treatment Revenue by Application (2017-2022)
Table 104. Global IBS Treatment Revenue Forecast by Application (2023-2028)
Table 105. North America IBS Treatment Revenue by Type (2017-2022) & (USD Million)
Table 106. North America IBS Treatment Revenue by Type (2023-2028) & (USD Million)
Table 107. North America IBS Treatment Revenue by Application (2017-2022) & (USD Million)
Table 108. North America IBS Treatment Revenue by Application (2023-2028) & (USD Million)
Table 109. North America IBS Treatment Revenue by Country (2017-2022) & (USD Million)
Table 110. North America IBS Treatment Revenue by Country (2023-2028) & (USD Million)
Table 111. Europe IBS Treatment Revenue by Type (2017-2022) & (USD Million)
Table 112. Europe IBS Treatment Revenue by Type (2023-2028) & (USD Million)
Table 113. Europe IBS Treatment Revenue by Application (2017-2022) & (USD Million)
Table 114. Europe IBS Treatment Revenue by Application (2023-2028) & (USD Million)
Table 115. Europe IBS Treatment Revenue by Country (2017-2022) & (USD Million)
Table 116. Europe IBS Treatment Revenue by Country (2023-2028) & (USD Million)
Table 117. Asia-Pacific IBS Treatment Revenue by Type (2017-2022) & (USD Million)
Table 118. Asia-Pacific IBS Treatment Revenue by Type (2023-2028) & (USD Million)
Table 119. Asia-Pacific IBS Treatment Revenue by Application (2017-2022) & (USD Million)
Table 120. Asia-Pacific IBS Treatment Revenue by Application (2023-2028) & (USD Million)
Table 121. Asia-Pacific IBS Treatment Revenue by Region (2017-2022) & (USD Million)
Table 122. Asia-Pacific IBS Treatment Revenue by Region (2023-2028) & (USD Million)
Table 123. South America IBS Treatment Revenue by Type (2017-2022) & (USD Million)
Table 124. South America IBS Treatment Revenue by Type (2023-2028) & (USD Million)
Table 125. South America IBS Treatment Revenue by Application (2017-2022) & (USD Million)
Table 126. South America IBS Treatment Revenue by Application (2023-2028) & (USD Million)
Table 127. South America IBS Treatment Revenue by Country (2017-2022) & (USD Million)
Table 128. South America IBS Treatment Revenue by Country (2023-2028) & (USD Million)
Table 129. Middle East & Africa IBS Treatment Revenue by Type (2017-2022) & (USD Million)
Table 130. Middle East & Africa IBS Treatment Revenue by Type (2023-2028) & (USD Million)
Table 131. Middle East & Africa IBS Treatment Revenue by Application (2017-2022) & (USD Million)
Table 132. Middle East & Africa IBS Treatment Revenue by Application (2023-2028) & (USD Million)
Table 133. Middle East & Africa IBS Treatment Revenue by Country (2017-2022) & (USD Million)
Table 134. Middle East & Africa IBS Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. IBS Treatment Picture
Figure 2. Global IBS Treatment Revenue Market Share by Type in 2021
Figure 3. IBS-D
Figure 4. IBS-C
Figure 5. IBS-M
Figure 6. IBS Treatment Revenue Market Share by Application in 2021
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Research Laboratories Picture
Figure 10. Global IBS Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 11. Global IBS Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global IBS Treatment Revenue Market Share by Region (2017-2028)
Figure 13. Global IBS Treatment Revenue Market Share by Region in 2021
Figure 14. North America IBS Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Europe IBS Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Asia-Pacific IBS Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. South America IBS Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Middle East and Africa IBS Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. IBS Treatment Market Drivers
Figure 20. IBS Treatment Market Restraints
Figure 21. IBS Treatment Market Trends
Figure 22. Allergan (Ireland) Recent Developments and Future Plans
Figure 23. Sucampo Pharmaceuticals (U.S.) Recent Developments and Future Plans
Figure 24. Ironwood Pharmaceuticals (U.S.) Recent Developments and Future Plans
Figure 25. Astellas Pharma (Japan) Recent Developments and Future Plans
Figure 26. Bausch Health Recent Developments and Future Plans
Figure 27. Abbott Laboratories (U.S.) Recent Developments and Future Plans
Figure 28. Synergy Pharmaceuticals (U.S.) Recent Developments and Future Plans
Figure 29. Ardelyx (U.S.) Recent Developments and Future Plans
Figure 30. Nestle (Switzerland) Recent Developments and Future Plans
Figure 31. Sebela Pharmaceuticals (Ireland) Recent Developments and Future Plans
Figure 32. Probi (Sweden) Recent Developments and Future Plans
Figure 33. Alfasigma USA (Italy) Recent Developments and Future Plans
Figure 34. RedHill Biopharma (Israel) Recent Developments and Future Plans
Figure 35. AstraZeneca (U.K) Recent Developments and Future Plans
Figure 36. Ipsen (France) Recent Developments and Future Plans
Figure 37. Novartis (Switzerland) Recent Developments and Future Plans
Figure 38. Takeda Pharmaceutical Company (Japan) Recent Developments and Future Plans
Figure 39. Synthetic Biologics (U.S.) Recent Developments and Future Plans
Figure 40. Protagonist Therapeutics (U.S.) Recent Developments and Future Plans
Figure 41. Pfizer (U.S.) Recent Developments and Future Plans
Figure 42. Lexicon Pharmaceuticals (U.S.) Recent Developments and Future Plans
Figure 43. Innovate Biopharmaceuticals (U.S.) Recent Developments and Future Plans
Figure 44. Global IBS Treatment Revenue Share by Players in 2021
Figure 45. IBS Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 46. Global Top 3 Players IBS Treatment Revenue Market Share in 2021
Figure 47. Global Top 10 Players IBS Treatment Revenue Market Share in 2021
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 49. Global IBS Treatment Revenue Share by Type in 2021
Figure 50. Global IBS Treatment Market Share Forecast by Type (2023-2028)
Figure 51. Global IBS Treatment Revenue Share by Application in 2021
Figure 52. Global IBS Treatment Market Share Forecast by Application (2023-2028)
Figure 53. North America IBS Treatment Sales Market Share by Type (2017-2028)
Figure 54. North America IBS Treatment Sales Market Share by Application (2017-2028)
Figure 55. North America IBS Treatment Revenue Market Share by Country (2017-2028)
Figure 56. United States IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Canada IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Mexico IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Europe IBS Treatment Sales Market Share by Type (2017-2028)
Figure 60. Europe IBS Treatment Sales Market Share by Application (2017-2028)
Figure 61. Europe IBS Treatment Revenue Market Share by Country (2017-2028)
Figure 62. Germany IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. France IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. United Kingdom IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Russia IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Italy IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Asia-Pacific IBS Treatment Sales Market Share by Type (2017-2028)
Figure 68. Asia-Pacific IBS Treatment Sales Market Share by Application (2017-2028)
Figure 69. Asia-Pacific IBS Treatment Revenue Market Share by Region (2017-2028)
Figure 70. China IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Japan IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. South Korea IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. India IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Southeast Asia IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Australia IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South America IBS Treatment Sales Market Share by Type (2017-2028)
Figure 77. South America IBS Treatment Sales Market Share by Application (2017-2028)
Figure 78. South America IBS Treatment Revenue Market Share by Country (2017-2028)
Figure 79. Brazil IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Argentina IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Middle East and Africa IBS Treatment Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa IBS Treatment Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa IBS Treatment Revenue Market Share by Country (2017-2028)
Figure 84. Turkey IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Saudi Arabia IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. UAE IBS Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
